The case for Oragenics (NYSE American: OGEN) as a clinical-stage story is real: three active Australian trial sites, nine participants dosed on ONP-002, and FDA responses already arriving on the U.S. regulatory pathway. What complicates it is a second deficiency letter from NYSE American, flagging the same equity shortfall the company only cleared in October 2025.
NYSE American notified Oragenics on August 26, 2026 that it is out of compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The two provisions require listed companies reporting sustained net losses to maintain stockholders' equity of at least $4 million and $6 million, respectively. Oragenics has 45 days from receipt of the letter to submit a compliance plan. If NYSE American accepts it, Oragenics can remain listed during a cure period, subject to periodic review by exchange staff. The outer deadline for full compliance is February 25, 2028; failure to meet that date, or to show adequate progress along the way, would trigger delisting procedures.
The risk is that equity thresholds do not move; the company's ability to satisfy them does. A second trip to the compliance window for the same standard it cleared in October 2025 suggests capital formation has not kept pace with clinical spending. Management says it intends to pursue a transaction or transactions to restore compliance, but that remains conditional language, with no terms or timeline attached.
The counterargument sits in the trial itself. Alfred Health, Mackay, and Royal Adelaide Hospital are all actively dosing participants in the Phase IIa feasibility trial for ONP-002, Oragenics' intranasal candidate for mild traumatic brain injury. CEO Janet Huffman pointed to the enrollment pace in Australia and constructive FDA engagement on the company's Type B meeting request briefing package, which was submitted in July 2026 and has already drawn agency responses. The company's stated goal is an Investigational New Drug application filed with the FDA by the end of 2026. A completed IND would give Oragenics a U.S. regulatory anchor, the kind of asset that can support a capital raise.
On balance, the read-through here is a capital story wearing clinical clothes. The line to watch is February 25, 2028.